June 6, 2018 07:05 AM EDT

FDA vet — and Woodcock nemesis — John Jenkins is stepping over to a new role as a board member at Corbus Pharma

Brittany Meiling

After making headlines for his part in the FDA’s painful rupture over Sarepta’s Duchenne approval, news of John Jenkins has been rather slow. But now …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA vet — and Woodcock nemesis — John Jenkins is stepping over to a new role as a board member at Corbus Pharma

Brittany Meiling

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Sofinnova outlines $550M fund after IPOs and M&A deals

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

FDA vet — and Wood­cock neme­sis — John Jenk­ins is step­ping over to a new role as a board mem­ber at Cor­bus Phar­ma

Brittany Meiling

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

FDA vet — and Woodcock nemesis — John Jenkins is stepping over to a new role as a board member at Corbus Pharma

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Sofinnova outlines $550M fund after IPOs and M&A deals

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.